HK1250142A1 - 以組織蛋白去乙醯酶抑制劑及反細胞程式死亡受體-1 抗體的組合治療癌症 - Google Patents

以組織蛋白去乙醯酶抑制劑及反細胞程式死亡受體-1 抗體的組合治療癌症

Info

Publication number
HK1250142A1
HK1250142A1 HK18109582.5A HK18109582A HK1250142A1 HK 1250142 A1 HK1250142 A1 HK 1250142A1 HK 18109582 A HK18109582 A HK 18109582A HK 1250142 A1 HK1250142 A1 HK 1250142A1
Authority
HK
Hong Kong
Prior art keywords
antibody
cancer
treatment
combination
hdac inhibitor
Prior art date
Application number
HK18109582.5A
Other languages
English (en)
Inventor
Robert Goodenow
Peter Ordentlich
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of HK1250142A1 publication Critical patent/HK1250142A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
HK18109582.5A 2015-03-20 2018-07-24 以組織蛋白去乙醯酶抑制劑及反細胞程式死亡受體-1 抗體的組合治療癌症 HK1250142A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562136303P 2015-03-20 2015-03-20
US201562137601P 2015-03-24 2015-03-24
PCT/US2016/023298 WO2016154068A1 (en) 2015-03-20 2016-03-18 Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer

Publications (1)

Publication Number Publication Date
HK1250142A1 true HK1250142A1 (zh) 2018-11-30

Family

ID=56977796

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18109582.5A HK1250142A1 (zh) 2015-03-20 2018-07-24 以組織蛋白去乙醯酶抑制劑及反細胞程式死亡受體-1 抗體的組合治療癌症

Country Status (12)

Country Link
US (2) US11324822B2 (zh)
EP (1) EP3270966B1 (zh)
JP (2) JP2018508593A (zh)
KR (1) KR20170124604A (zh)
CN (1) CN107614011A (zh)
AU (2) AU2016235434B2 (zh)
BR (1) BR112017020002A2 (zh)
CA (1) CA2980297A1 (zh)
HK (1) HK1250142A1 (zh)
IL (2) IL307850A (zh)
MX (1) MX2017012113A (zh)
WO (1) WO2016154068A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CA2994731C (en) * 2015-09-02 2023-09-26 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
WO2017120204A2 (en) * 2016-01-05 2017-07-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
AU2017211383A1 (en) * 2016-01-28 2018-08-16 Indiana University Research & Technology Corporation Use of histone deacetylase inhibitors for enhancing immunotherapies
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
JP7090611B2 (ja) * 2016-11-23 2022-06-24 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド１（ｐｄ－ｌ１）阻害剤とを含む医薬組み合わせ物及びその使用方法
TW201919614A (zh) * 2017-09-08 2019-06-01 德商４Ｓｃ製藥公司 Hdac抑制劑與免疫檢查點調節劑組合用於癌症治療
WO2019191764A1 (en) * 2018-03-28 2019-10-03 Ensemble Group Holdings Methods of treating cancer in subjects having dysregulated lymphatic systems
EP3843718A1 (en) * 2018-06-15 2021-07-07 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
KR20210028339A (ko) * 2019-09-04 2021-03-12 크리스탈지노믹스(주) Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
TW202128224A (zh) * 2019-12-23 2021-08-01 大陸商信達生物製藥（蘇州）有限公司 抗ｐｄ－１抗體和組蛋白去乙醯化酶抑制劑的藥物組合及其用途、使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US20130150386A1 (en) 2011-12-09 2013-06-13 Syndax Pharmaceuticals, Inc. Methods for the treatment of lung cancer
US8987067B2 (en) * 2013-03-01 2015-03-24 International Business Machines Corporation Segmented guard ring structures with electrically insulated gap structures and design structures thereof
AU2014296887A1 (en) * 2013-08-02 2016-01-28 Aduro Biotech Holdings, Europe B.V. Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
WO2015035112A1 (en) 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
US9987258B2 (en) * 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
WO2016010879A1 (en) * 2014-07-15 2016-01-21 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
CN114920840A (zh) * 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
EP3313433A4 (en) * 2015-06-29 2019-01-02 Syndax Pharmaceuticals Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
CA2994731C (en) * 2015-09-02 2023-09-26 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy

Also Published As

Publication number Publication date
RU2017134315A (ru) 2019-04-03
US11324822B2 (en) 2022-05-10
US20230022573A1 (en) 2023-01-26
KR20170124604A (ko) 2017-11-10
IL254529B2 (en) 2024-05-01
EP3270966A4 (en) 2018-10-17
AU2022202954A1 (en) 2022-05-26
JP2021175754A (ja) 2021-11-04
JP2018508593A (ja) 2018-03-29
EP3270966A1 (en) 2018-01-24
AU2016235434B2 (en) 2022-02-03
WO2016154068A1 (en) 2016-09-29
IL254529A0 (en) 2017-11-30
BR112017020002A2 (pt) 2018-06-19
CN107614011A (zh) 2018-01-19
IL307850A (en) 2023-12-01
US20180078639A1 (en) 2018-03-22
RU2017134315A3 (zh) 2019-09-12
EP3270966B1 (en) 2024-05-01
IL254529B1 (en) 2024-01-01
MX2017012113A (es) 2018-07-06
AU2016235434A1 (en) 2017-10-12
CA2980297A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
HK1250142A1 (zh) 以組織蛋白去乙醯酶抑制劑及反細胞程式死亡受體-1 抗體的組合治療癌症
HK1255916A1 (zh) 組織蛋白去乙醯酶抑制劑與免疫檢查點抑制抗體的合併癌症治療
IL282962A (en) Anti-PD-1 antibodies and methods of using them
HK1250513A1 (zh) 抗ox40抗體及其使用方法
IL258955A (en) Preparations and methods for the treatment of cancer
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
IL262562A (en) Combination of anti-pd-1 antibodies and radiation for cancer therapy
EP3383914A4 (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE
IL254131A0 (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
IL259713A (en) Anti-dr5 antibodies and methods of using them
IL289766A (en) tfpi inhibitory antibodies and their uses
GB201712905D0 (en) Treatment of cancer with anti-lap monoclonal antibodies
DK3178849T3 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
IL259416A (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
IL269718A (en) Combination of anti-PD-L1 antibody and DNA-PK inhibitor for cancer treatment
EP3370773A4 (en) POLYTHERAPY COMPRISING IMMUNOTOXINS AND A CONTROL POINT INHIBITOR
IL274198A (en) Use of Nox inhibitors to treat cancer
EP3727374A4 (en) COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND AN IDO1 INHIBITOR FOR THE TREATMENT OF CANCER
EP3126520A4 (en) Biomarkers and use of met inhibitor for treatment of cancer
GB201418640D0 (en) Agents and methods for treatment of cancer